Cargando…
A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma
BACKGROUND: We aimed to construct a clinical-radiomics nomogram to predict disease-free survival (DFS) and the added survival benefit of adjuvant chemotherapy (ACT) for node-negative, early-stage (I–II) lung adenocarcinoma (ADC). METHODS: In this retrospective study including 310 patients from two i...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828517/ https://www.ncbi.nlm.nih.gov/pubmed/35242363 http://dx.doi.org/10.21037/jtd-21-1520 |
_version_ | 1784647864290377728 |
---|---|
author | Ma, Xiaoling Lv, Wenzhi Wang, Cong Tu, Dehao Qiao, Jinhan Fan, Chanyuan Niu, Jiandong Zhou, Wen Liu, Qiuyu Xia, Liming |
author_facet | Ma, Xiaoling Lv, Wenzhi Wang, Cong Tu, Dehao Qiao, Jinhan Fan, Chanyuan Niu, Jiandong Zhou, Wen Liu, Qiuyu Xia, Liming |
author_sort | Ma, Xiaoling |
collection | PubMed |
description | BACKGROUND: We aimed to construct a clinical-radiomics nomogram to predict disease-free survival (DFS) and the added survival benefit of adjuvant chemotherapy (ACT) for node-negative, early-stage (I–II) lung adenocarcinoma (ADC). METHODS: In this retrospective study including 310 patients from two independent cohorts, the CT-derived radiomics features were selected by least absolute shrinkage and selection operator Cox regression to generate a radiomics signature associated with DFS. The radiomics signature was incorporated to construct a clinical-radiomics nomogram along with the independent clinical risk predictors. The model performance was evaluated with reference to discrimination quantified by Harrell concordance index (C-index), integrated discrimination improvement (IDI) and net reclassification index (NRI), calibration and clinical utility. The risk score (RS) for clinical-radiomics nomogram was calculated. The association between ACT and survival benefit was assessed in high and low RS subgroup. RESULTS: The clinical-radiomics nomogram achieved the highest C-index of 0.822 [95% confidence interval (CI): 0.769, 0.876] in training cohort and 0.802 (95% CI: 0.716, 0.888) in validation cohort. The incorporation of radiomics signature into clinical-radiomics nomogram showed an incremental benefit over clinical nomogram according to the improved NRI and IDI. The calibration curves and decision curve analysis further verified the clinical utility of clinical-radiomics nomogram. Further, patients with high RS based on clinical-radiomics nomogram were more prone to benefit from ACT. CONCLUSIONS: The clinical-radiomics nomogram approach can feasibly conduct risk prediction and have potential to identify the beneficiaries of ACT among patients with node-negative, early-stage ADC, which might serve as a helpful tool in informing therapeutic decision-making. |
format | Online Article Text |
id | pubmed-8828517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-88285172022-03-02 A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma Ma, Xiaoling Lv, Wenzhi Wang, Cong Tu, Dehao Qiao, Jinhan Fan, Chanyuan Niu, Jiandong Zhou, Wen Liu, Qiuyu Xia, Liming J Thorac Dis Original Article BACKGROUND: We aimed to construct a clinical-radiomics nomogram to predict disease-free survival (DFS) and the added survival benefit of adjuvant chemotherapy (ACT) for node-negative, early-stage (I–II) lung adenocarcinoma (ADC). METHODS: In this retrospective study including 310 patients from two independent cohorts, the CT-derived radiomics features were selected by least absolute shrinkage and selection operator Cox regression to generate a radiomics signature associated with DFS. The radiomics signature was incorporated to construct a clinical-radiomics nomogram along with the independent clinical risk predictors. The model performance was evaluated with reference to discrimination quantified by Harrell concordance index (C-index), integrated discrimination improvement (IDI) and net reclassification index (NRI), calibration and clinical utility. The risk score (RS) for clinical-radiomics nomogram was calculated. The association between ACT and survival benefit was assessed in high and low RS subgroup. RESULTS: The clinical-radiomics nomogram achieved the highest C-index of 0.822 [95% confidence interval (CI): 0.769, 0.876] in training cohort and 0.802 (95% CI: 0.716, 0.888) in validation cohort. The incorporation of radiomics signature into clinical-radiomics nomogram showed an incremental benefit over clinical nomogram according to the improved NRI and IDI. The calibration curves and decision curve analysis further verified the clinical utility of clinical-radiomics nomogram. Further, patients with high RS based on clinical-radiomics nomogram were more prone to benefit from ACT. CONCLUSIONS: The clinical-radiomics nomogram approach can feasibly conduct risk prediction and have potential to identify the beneficiaries of ACT among patients with node-negative, early-stage ADC, which might serve as a helpful tool in informing therapeutic decision-making. AME Publishing Company 2022-01 /pmc/articles/PMC8828517/ /pubmed/35242363 http://dx.doi.org/10.21037/jtd-21-1520 Text en 2022 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Original Article Ma, Xiaoling Lv, Wenzhi Wang, Cong Tu, Dehao Qiao, Jinhan Fan, Chanyuan Niu, Jiandong Zhou, Wen Liu, Qiuyu Xia, Liming A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma |
title | A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma |
title_full | A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma |
title_fullStr | A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma |
title_full_unstemmed | A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma |
title_short | A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma |
title_sort | potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828517/ https://www.ncbi.nlm.nih.gov/pubmed/35242363 http://dx.doi.org/10.21037/jtd-21-1520 |
work_keys_str_mv | AT maxiaoling apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT lvwenzhi apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT wangcong apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT tudehao apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT qiaojinhan apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT fanchanyuan apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT niujiandong apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT zhouwen apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT liuqiuyu apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT xialiming apotentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT maxiaoling potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT lvwenzhi potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT wangcong potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT tudehao potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT qiaojinhan potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT fanchanyuan potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT niujiandong potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT zhouwen potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT liuqiuyu potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma AT xialiming potentialbiomarkerbasedonclinicalradiomicsnomogramforpredictingsurvivalandadjuvantchemotherapybenefitinresectednodenegativeearlystagelungadenocarcinoma |